Ranolazine Induced Bradycardia, Renal Failure, and Hyperkalemia: A BRASH Syndrome Variant

Ranolazine is a well-known antianginal drug, that was first licensed for use in the United States in 2006. It was objectively shown to improve exercise capacity and to lengthen the time to symptom onset in patients with coronary artery disease. The most commonly reported side effects of ranolazine i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaidi, Syed Arsalan Akhter, Shaikh, Danial, Saad, Muhammad, Vittorio, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955118/
https://www.ncbi.nlm.nih.gov/pubmed/31975993
http://dx.doi.org/10.1155/2019/2740617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955118/
https://www.ncbi.nlm.nih.gov/pubmed/31975993
http://dx.doi.org/10.1155/2019/2740617

Ejemplares similares